Skip to main content
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
    • CME
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CCR Focus Archive
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citation
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in

Search

  • Advanced search
Clinical Cancer Research
Clinical Cancer Research

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
    • CME
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CCR Focus Archive
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citation
    • Author/Keyword
  • News
    • Cancer Discovery News
Letters to the Editor

Does Erythropoietin Promote Tumor Growth?

Pierre Saintigny, Benjamin Besse, Jean-Charles Soria, Jean-François Bernaudin and Patrice Callard
Pierre Saintigny
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Benjamin Besse
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jean-Charles Soria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jean-François Bernaudin
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Patrice Callard
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1078-0432.CCR-07-4884 Published March 2008
  • Article
  • Info & Metrics
  • PDF
Loading

In Response: We appreciate Yoon and colleagues' interest in our report and welcome the opportunity to reply to their comments. Our study was designed in a context in which several clinical trials, including patients with head and neck squamous cell carcinomas, breast cancer, non–small cell lung cancer and nonmyeloid malignancies, showed a potential deleterious effect of recombinant human erythropoietin on survival (1–6). A recently published meta-analysis of 57 randomized controlled trials that compared the use of recombinant human erythropoietin with a placebo indicated that treatment, compared with no treatment, was associated with a trend towards decreased survival (hazard ratio, 1.08; 95% confidence interval, 0.99-1.18; ref. 7). All these data prompted the Food and Drug Administration to release a Public Health Advisory bulletin including a boxed warning and additional labeling revisions that have been recently updated (8). Because so many patients receive recombinant human erythropoietin each year to improve their quality of life, it is therefore urgent to better understand the role of endogenous erythropoietin (EPO) and its receptor (EPOR).

In a preliminary study, we reported in a limited series of patients with non–small cell lung cancer that EPO/EPOR coexpression was frequent at both the mRNA and protein levels, confirming reports established in other solid tumors (9). We then believed that it was crucial to evaluate EPO/EPOR coexpression in tumor cells as a prognostic factor. Because our objective was to explore the role of EPO/EPOR coexpression in tumor cells, we chose patients with stage I non–small cell lung cancer to avoid confounding factors associated with advanced disease, the use of chemotherapy, and the potential use of recombinant human erythropoietin.

Yoon et al. point out the use of C-20 and H-162 polyclonal antibodies. In fact, the proposed experiment to test the speci and coworkers ficity of EPOR and EPO immunoreactivity has been previously reported with these antibodies (10). The antibody absorption test by preincubating the primary antibody with blocking peptide for EPOR or human recombinant EPO resulted in the complete abolishment of immunohistochemical staining. Even if the conclusions of Elliot et al. have been challenged (11, 12), we agree that C-20 antibody specificity is probably not perfect, as is the case with most commercial antibodies available against EPOR. We strongly disagree, however, when Yoon et al. state that H-162 antibody against EPO also has a low specificity as there is no scientific reference for this statement. Mohyeldin et al. showed the H-162 specificity by both absorption test and after comparison with a mouse monoclonal antibody anti-EPO (clone 9C21D11; R&D Systems), which resulted in an immunostaining pattern similar to that obtained in their study from formalin-fixed paraffin-embedded sections (13). Many investigators have therefore used H-162 antibody successfully for immunohistochemistry in paraffin-embedded tumors (14–16).

Furthermore, to circumvent this potential lack of specificity, we considered high levels of EPOR and EPO staining versus low levels of expression, and evaluated the effect of EPO/EPOR coexpression. Our blinded evaluation by two investigators (P. Callard and P. Saintigny) was highly reproducible. In our multivariate analysis, we showed that in this population, high levels of EPO expression and high levels of EPO/EPOR coexpression are independent prognostic factors for disease-specific survival. In other words, high levels of EPO/EPOR coexpression in 11% of our population was associated with a hazard ratio ∼2 to die from the disease. Our interpretation is that it is very unlikely that nonspecific staining of both EPO and EPOR could give rise to such results. As discussed in our article, in at least two recent studies, EPOR gene overexpression appeared as a significant player of NSCLC behavior, thereby confirming its biological relevance (17, 18).

Yoon et al. claim that we mainly detected EPO and EPOR in the cytoplasm of tumor cells and that addressing the question of endogenous EPO/EPOR activity is crucial. We agree with this statement and evaluation of intracellular signaling is currently under investigation. In our previous work, we did not find any relation between EPO/EPOR coexpression and Ki67 staining (9). As in other nonhematopoietic cells, however, EPO might act in a tissue-protective manner and exert an antiapoptotic effect on tumor cells (18). Recent studies using recombinant soluble EPOR, an anti-EPO monoclonal antibody, or a secreted EPO antagonist protein (EPOR) in ovarian and breast cancer models show an inhibition of tumor angiogenesis, an inhibition of cancer cell growth and of survival underlying a potential autocrine/paracrine role of secreted EPO on tumor cells and endothelial cells (19, 20). Functional preclinical work on patient-derived cell lines should help clarify this topic.

The potential dark side of erythropoietin in cancer cells has to be more deeply investigated (21). We believe that it would be more productive for all recombinant human erythropoietin stakeholders to help produce a highly specific monoclonal antibody against EPOR rather than highlighting the lack of specificity of available commercial antibodies.

    References

    1. ↵
      Henke M, Laszig R, Rube C, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomized, double-blind, placebo-controlled trial. Lancet 2003;362:1255–60.
      OpenUrlCrossRefPubMed
    2. Machtay M, Pajak TF, Suntharalingam M, et al. Radiotherapy with or without erythropoietin for anemic patients with head and neck cancer: a randomized trial of the Radiation Therapy Oncology Group (RTOG 99-03). Int J Radiation Oncology Biol Phys 2008;69:1008–7.
      OpenUrl
    3. Leyland-Jones B, Semiglazov V, Pawlicki M, et al. Maintaining normal hemoglobin levels with epoietin alpha in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol 2005;23:5960–72.
      OpenUrlAbstract/FREE Full Text
    4. Konstantinopoulos PA, Karamouzis MV, Papavassiliou AG. Selective modulation of the erythropoietic and tissue-protective effects of erythropoietin: time to reach the full therapeutic potential of erythropoietin. Biochim Biophys Acta 2007;1776:1–9.
      OpenUrlPubMed
    5. Wright JR, Ung YC, Julian JA, et al. Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small cell lung cancer with disease-related anemia. J Clin Oncol 2007;25:1027–32.
      OpenUrlAbstract/FREE Full Text
    6. ↵
      U.S. Food and Drug Administration, http://www.fda.gov/medwatch/safety/2007/safety07.htm#ESA, accessed November 2007.
    7. ↵
      Bohlius J, Wilson J, Seidenfeld J, et al. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst 2006;98:708–14.
      OpenUrlAbstract/FREE Full Text
    8. ↵
      U.S. Food and Drug Administration, http://www.fda.gov/cder/drug/infopage/RHE/default.htm, accessed November, 2007.
    9. ↵
      Dagnon K, Pacary E, Commo F, et al. Expression of erythropoietin and erythropoietin receptor in non-small cell lung carcinomas. Clin Cancer Res 2005;11:993–9.
      OpenUrlAbstract/FREE Full Text
    10. ↵
      Acs G, Acs P, Beckwith SM, et al. Erythropoietin and erythropoietin receptor expression in human cancer. Cancer Res 2001;61:3561–5.
      OpenUrlAbstract/FREE Full Text
    11. ↵
      Elliott S, Busse L, Bass MB, et al. Anti-Epo receptor antibodies do not predict Epo receptor expression. Blood 2006;107:1892–5.
      OpenUrlAbstract/FREE Full Text
    12. ↵
      Henke M, Verma A, Acs G. Erythropoietin receptors on cancer cells: exciting perspectives, difficult to appreciate. Blood 2006;108:1107–8.
      OpenUrlFREE Full Text
    13. ↵
      Mohyeldin A, Lu H, Dalgard C, et al. Erythropoietin signaling promotes invasiveness of human head and neck squamous cell carcinoma. Neoplasia 2005;7:537–43.
      OpenUrlCrossRefPubMed
    14. ↵
      Pelekanou V, Kampa M, Kafousi M, et al. Erythropoietin and its receptor in breast cancer: correlation with steroid receptors and outcome. Cancer Epidemiol Biomarkers Prev 2007;16:2016–23.
      OpenUrlAbstract/FREE Full Text
    15. Fantacci M, Bianciardi P, Caretti A, et al. Carbamylated erythropoietin ameliorates the metabolic stress induced in vivo by severe chronic hypoxia. Proc Natl Acad Sci U S A 2006;103:17531–6.
      OpenUrlAbstract/FREE Full Text
    16. ↵
      Kumar SM, Acs G, Fang D, Herlyn M, Elder DE, Xu X. Functional erythropoietin autocrine loop in melanoma. Am J Pathol 2005;166:823–30.
      OpenUrlPubMed
    17. ↵
      Potti A, Mukherjee S, Petersen R, et al. A genomic strategy to refine prognosis in early-stage nonsmall-cell lung cancer. N Engl J Med 2006;355:570–80.
      OpenUrlCrossRefPubMed
    18. ↵
      Takada M, Tada M, Tamoto E, et al. Prediction of lymph node metastasis by analysis of gene expression profiles in non-small-cell lung cancer. J Surg Res 2004;122:61–9.
      OpenUrlCrossRefPubMed
    19. ↵
      Jeong JY, Feldman L, Solar P, Szenajch J, Sytkowski AJ. Characterization of erythropoietin receptor and erythropoietin expression and function in human ovarian cancer cells. Int J Cancer 2008;122:274–80.
      OpenUrlCrossRefPubMed
    20. ↵
      Hardee ME, Cao Y, Fu P, et al. Erythropoietin blockade inhibits the induction of tumor angiogenesis and progression. PLoS ONE 2007;2:e549.
    21. ↵
      Sytkowski AJ. Does erythropoietin have a dark side? Epo signaling in cancer cells. Sci STKE 2007;395:pe38.
    PreviousNext
    Back to top
    Clinical Cancer Research: 14 (6)
    March 2008
    Volume 14, Issue 6
    • Table of Contents
    • Table of Contents (PDF)
    • About the Cover
    • Index by Author

    Sign up for alerts

    View this article with LENS

    Open full page PDF
    Article Alerts
    Sign In to Email Alerts with your Email Address
    Email Article

    Thank you for sharing this Clinical Cancer Research article.

    NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

    Enter multiple addresses on separate lines or separate them with commas.
    Does Erythropoietin Promote Tumor Growth?
    (Your Name) has forwarded a page to you from Clinical Cancer Research
    (Your Name) thought you would be interested in this article in Clinical Cancer Research.
    Citation Tools
    Does Erythropoietin Promote Tumor Growth?
    Pierre Saintigny, Benjamin Besse, Jean-Charles Soria, Jean-François Bernaudin and Patrice Callard
    Clin Cancer Res March 15 2008 (14) (6) 1920-1921; DOI: 10.1158/1078-0432.CCR-07-4884

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
    Share
    Does Erythropoietin Promote Tumor Growth?
    Pierre Saintigny, Benjamin Besse, Jean-Charles Soria, Jean-François Bernaudin and Patrice Callard
    Clin Cancer Res March 15 2008 (14) (6) 1920-1921; DOI: 10.1158/1078-0432.CCR-07-4884
    del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
    • Tweet Widget
    • Facebook Like
    • Google Plus One

    Jump to section

    • Article
      • References
    • Info & Metrics
    • PDF
    Advertisement

    Related Articles

    Cited By...

    More in this TOC Section

    • Genomics of Immunotherapy-Associated Hyperprogressors—Response
    • Hyper-progressors after Immunotherapy, Genomic Alterations
    • Individualized Pazopanib Dosing—Letter
    Show more Letters to the Editor
    • Home
    • Alerts
    • Feedback
    Facebook  Twitter  LinkedIn  YouTube  RSS

    Articles

    • Online First
    • Current Issue
    • Past Issues
    • CCR Focus Archive
    • Meeting Abstracts

    Info for

    • Authors
    • Subscribers
    • Advertisers
    • Librarians
    • Reviewers

    About Clinical Cancer Research

    • About the Journal
    • Editorial Board
    • Permissions
    • Submit a Manuscript
    AACR logo

    Copyright © 2018 by the American Association for Cancer Research.

    Clinical Cancer Research
    eISSN: 1557-3265
    ISSN: 1078-0432

    Advertisement